|
History
The Genetics Company Inc. (a Swiss "Aktiengesellschaft") was founded in July 1998 based on research performed at the University of Zurich and at the Swiss Institute for Experimental Cancer Research (ISREC) in Epalinges / Lausanne. The Company became fully operational upon the closing of its Series A financing round in May of 2000 (see Financing).
Originally focused mainly on cancer, the Company in December 2002 acquired the core assets from CallistoGen AG of Berlin including small molecule hit series against Alzheimer’s disease, proprietary "in silico" medicinal chemistry tools and corresponding intellectual property. To complement its capabilities in the field of Alzheimer’s disease a further asset acquisition was executed in May 2003, bringing to its portfolio a set of newly developed products for use in the diagnosis, monitoring of drugs and also the research of Alzheimer’s disease, as well as intellectual property for novel therapeutic approaches. These assets were acquired from ABETA GmbH of Heidelberg, Germany in a cash plus shares transaction.
The Company today is pursuing the commercialization of its assets in the cancer and Alzheimer’s disease markets, both of which have an outstanding potential due to the largely unmet medical needs present. The Alzheimer’s diagnostics business is profitable and provides for substantial revenues. Its proprietary drug leads for the treatment of colorectal cancer and Alzheimer’s disease, both in pre-clinical development, represent an outstanding medium- to long-term revenue and exit potential for investors.
The Company was successful in raising a total of CHF 50.5 million in venture capital in three financing rounds since year 2000 and has therefore secured sufficient funding to develop a drug candidate into early clinical testing either independently or else with an appropriate partner.
Today the Company employs a staff of 8 and operates from a state-of-the-art facility at the Biotech Center Zurich in Schlieren in close proximity to both the University of Zurich and the ETH Zurich.
Please contact Dr. Mátyás Vegh, CEO The Genetics Company, Inc. by phone on +41 44 200 22 00 should you require any further information.
|
